Another notable example is bevacizumab (Avastin, Genentech/Roche), a humanized monoclonal anti-VEGF IgG that has received regulatory approval from the US Food and Drug Administration (FDA) for first-line treatment of metastatic colorectal cancer, non-small-cell lung cancer (NSCLC), metastatic renal cell carcinoma, and recurrent GBM in combination with other anticancer therapies54. Here, VEGFA is linked to non-small cell lung carcinoma.